Viewing data from:

FENTANYL-25

ANDA

FENTANYL | A076258 | MYLAN TECHNOLOGIES INC

8 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-10-21 | 7 NDCs

Highest NADAC/Unit

$57.69

per ea

Lowest NADAC/Unit

$6.07

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00378912698FENTANYL 62.5 MCG/HR PATCH	$57.69	EA	Generic	—	2026-10-21
00378912598FENTANYL 37.5 MCG/HR PATCH	$36.19	EA	Generic	—	2026-10-21
00378912498FENTANYL 100 MCG/HR PATCH	$19.62	EA	Generic	—	2026-10-21
00378912398FENTANYL 75 MCG/HR PATCH	$15.80	EA	Generic	—	2026-10-21
00378911998FENTANYL 12 MCG/HR PATCH	$9.37	EA	Generic	—	2026-10-21
00378912298FENTANYL 50 MCG/HR PATCH	$9.07	EA	Generic	—	2026-10-21
00378912198FENTANYL 25 MCG/HR PATCH	$6.07	EA	Generic	—	2026-10-21

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 8 NDCs (8 FSS)

Lowest Price

$6.45

Highest Price

$405.31

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00378-9119-98FENTANYL 12 MCG/HR PATCH	$34.90	FSS	Mylan Pharmaceuticals, Inc.	12/31/2027
00378-9121-98FENTANYL 25MCG/HR PATCH	$6.45	FSS	Mylan Pharmaceuticals, Inc.	12/31/2027
00378-9122-98FENTANYL 50MCG/HR PATCH	$12.03	FSS	Mylan Pharmaceuticals, Inc.	12/31/2027
00378-9123-98FENTANYL 75MCG/HR PATCH	$18.11	FSS	Mylan Pharmaceuticals, Inc.	12/31/2027
00378-9124-98FENTANYL 100MCG/HR PATCH	$38.10	FSS	Mylan Pharmaceuticals, Inc.	12/31/2027
00378-9125-98FENTANYL 37.5MCG/HR PATCH	$204.86	FSS	Mylan Pharmaceuticals, Inc.	12/31/2027
00378-9126-98FENTANYL 62.5MCG/HR PATCH	$297.68	FSS	Mylan Pharmaceuticals, Inc.	12/31/2027
00378-9127-98FENTANYL 87.5MCG/HR PATCH	$405.31	FSS	Mylan Pharmaceuticals, Inc.	12/31/2027

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain5 active DMFs8 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

VERANOVA LPFENTANYL BASE

DMF 62171986

SPECGX LLCFENTANYL ALKALOID

DMF 142851999

CAMBREX CHARLES CITY INCFENTANYL

DMF 168722003

CHATTEM CHEMICALS INCFENTANYL BASE USP

DMF 175952004

SIEGFRIED GRAFTON INCFENTANYL

DMF 181942005

CYGNUS INCInactiveFENTANYL TRANSDERMAL SYSTEM (FENTANYL TS) MFD IN REDWOOD CITY, CA

DMF 79491989

MALLINCKRODT CHEMICAL INCInactiveFENTANYL ALKALOID

DMF 80741989

ABBOTT LABORATORIESInactiveFENTANYL

DMF 90351991

CYGNUS INCInactiveFENTANYL TRANSDERMAL SYSTEM (FENTANYL TS)

DMF 94741991

CODY LABORATORIES INC A WHOLLY OWNED SUBSIDIARY OF LANNETT CO INCInactiveFENTANYL CITRATE ACTIVE INGREDIENT

DMF 175792004

CODY LABORATORIES INC A WHOLLY OWNED SUBSIDIARY OF LANNETT CO INCInactiveFENTANYL BASE USP

DMF 179162004

BOEHRINGER INGELHEIM CHEMICALS INCInactiveFENTANYL BASE

DMF 181392005

NORAMCO INCInactiveFENTANYL BASE

DMF 280372015

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

2 letters from Drugs@FDA

Date	Submission	Document
Feb 1, 2005	ORIG -1	View Letter (PDF)
Jun 24, 2004	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (8)

Sort:

#004 — 100MCG/HR

0 patents0 exclusivities▾

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Jan 28, 2005

#005 — 12.5MCG/HR

0 patents0 exclusivities▾

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Jan 23, 2007

#001 — 25MCG/HR

0 patents0 exclusivities▴

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Jan 28, 2005

No patent or exclusivity listings for this strength.

#006 — 37.5MCG/HR

0 patents0 exclusivities▾

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Dec 29, 2014

#002 — 50MCG/HR

0 patents0 exclusivities▾

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Jan 28, 2005

#007 — 62.5MCG/HR

0 patents0 exclusivities▾

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Dec 29, 2014

#003 — 75MCG/HR

0 patents0 exclusivities▾

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Jan 28, 2005

#008 — 87.5MCG/HR

0 patents0 exclusivities▾

FILM, EXTENDED RELEASE;TRANSDERMAL | Approved: Dec 29, 2014